List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
Founder and CSO of Achilles Therapeutics Dr Sergio Quezada reveals how the landmark TRACERx study has gleaned key insights that could make the difference between success and failure in immunotherapy treatment.
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
The first multi-chamber cardioids derived from hiPSCs have enabled scientists to investigate heart development and defects.
New software can make protein molecules that bind with high affinity and specificity to many biomarkers, including human hormones.
Understanding the mechanisms in lung formation could develop new therapeutic approaches for respiratory conditions.
Cancer treatment may be majorly impacted by new findings about the polymerase theta-mediated end joining time DNA repair pathway.
NETs require epidermal growth factor to grow, meaning that inhibiting EGF receptors could treat these types of tumours.
The new small molecule targets the glutamate system, reducing MS-like symptoms and repairing damaged myelin in two different animal models.
Astrocyte plasticity is correlated with upregulation of the Galectin 3 protein, which may greatly contribute to biomarker discovery.
Researchers found heightened SCAN enzyme activity in humans and mice with diabetes results in excessive nitric oxide on insulin receptors.
Discovery about the NPM1c variant could lead to new drugs targeting the cell growth of acute myeloid leukaemia.
By mapping the genome, scientists have discovered how IKAROS enables differentiation of hematopoietic stem cells into B cells.
Findings about how erythrocytes interact with brain capillaries offers new potential treatments for brain microhaemorrhages.
An advanced computational model enables scientists to study how cancer cells navigate through blood vessels.
This November edition of our Women in Stem series spotlights Andrea Pfeifer, CEO and Co-Founder of AC Immune SA. Dr Andrea Pfeifer co-founded AC Immune SA in 2003, since when she has served as a Director on the Board, successfully leading it to an IPO in 2016. Under her leadership,…
